Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -44.84 | — | — | — | 341.25 | 1011.11 | 18.97 | — | — | — | — | 96.88 | — | — | — | — | — | 0.59 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.06 | 1.56 | 1.73 | 1.85 | 3.19 | 3.95 | 2.02 | 2.23 | 1.85 | 1.23 | 2.88 | 1.05 | 1.28 | 0.76 | 0.65 | 0.48 | 0.30 | 0.13 | 0.52 | 1.72 | 2.57 |
| — | -60.4% | -14.3% | -17.0% | +71.8% | +222.3% | -29.7% | +112.6% | +45.3% | +61.6% | +344.7% | +118.5% | +328.0% | +470.1% | +23.8% | -72.0% | -88.4% | -95.4% | -79.0% | -4.0% | +71.2% | |
| P/B Ratio | 7.35 | 12.29 | 13.56 | 13.10 | 18.01 | 33.77 | 18.87 | — | — | — | — | — | — | — | — | 20.30 | 4.19 | 1.08 | 4.94 | 5.36 | 3.65 |
| — | -63.6% | -28.1% | — | — | — | — | — | — | — | — | — | — | — | — | +278.5% | +14.9% | -69.2% | +102.5% | +226.8% | +222.6% | |
| P/FCF | 3.68 | 31.41 | — | 3.45 | 6.68 | 11.10 | — | — | — | — | — | — | — | 11.78 | — | — | 0.43 | — | — | — | — |
| — | +182.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 11.37 | — | — | — | 33.31 | 15.67 | 7.32 | — | — | 101.83 | — | 5.60 | — | 141.51 | — | 9.41 | — | 0.33 | — | — | — |
| — | — | — | — | — | -84.6% | — | — | — | -28.0% | — | -40.5% | — | +42631.1% | — | — | — | — | — | — | — | |
| EV / EBIT | 11.98 | — | — | — | 26.90 | 31.88 | 7.29 | — | — | — | — | 29.70 | — | — | — | 3.71 | — | 0.42 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | +700.1% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.3% | 78.8% | 76.4% | 78.8% | 83.5% | 84.1% | 86.7% | 56.2% | 62.2% | 81.0% | 91.7% | 66.8% | 57.2% | 69.3% | 49.5% | 105.6% | 21.4% | 85.3% | 49.2% | 45.0% | 67.3% |
| — | -6.3% | -11.8% | +40.2% | +34.3% | +3.9% | -5.4% | -15.8% | +8.7% | +16.8% | +85.1% | -36.8% | +166.9% | -18.7% | +0.7% | +134.7% | -68.2% | +10695.0% | +45.4% | -14.6% | +36.2% | |
| Operating Margin | 9.9% | -12.9% | -8.8% | -14.8% | 7.6% | 22.6% | 23.6% | -30.8% | -33.4% | -20.0% | -45.8% | 2.4% | -31.0% | -16.0% | -64.0% | -11.5% | -103.5% | 27.0% | -94.8% | -113.3% | -112.6% |
| — | -157.1% | -137.2% | +51.8% | +122.7% | +212.8% | +151.5% | -1358.5% | -7.8% | -25.3% | +28.4% | +121.2% | +70.0% | -159.2% | +32.5% | +89.8% | +8.1% | +118.0% | +23.6% | +24.8% | -16.2% | |
| Net Margin | -2.3% | -18.1% | -16.9% | -21.2% | 0.9% | 0.4% | 10.7% | -49.0% | -53.5% | -19.7% | -55.2% | 1.1% | -34.5% | -19.8% | -67.2% | -13.7% | -111.0% | 23.3% | -101.2% | -121.1% | -122.1% |
| — | -4685.8% | -258.6% | +56.7% | +101.7% | +102.0% | +119.3% | -4588.7% | -55.4% | +0.8% | +17.9% | +108.0% | +69.0% | -185.0% | +33.6% | +88.7% | +9.1% | +114.9% | +23.9% | +21.1% | -22.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.4% | -34.0% | -30.2% | -33.0% | 1.5% | 0.9% | 24.9% | — | — | — | — | — | — | — | — | -79.1% | -142.1% | 66.6% | -124.7% | -66.2% | -38.2% |
| — | -3803.8% | -221.4% | — | — | — | — | — | — | — | — | — | — | — | — | -19.6% | -272.0% | +255.8% | -313.5% | -115.1% | -119.2% | |
| ROA | -1.8% | -2.5% | -2.5% | -3.3% | 0.2% | 0.1% | 2.3% | -10.7% | -9.4% | -3.9% | -7.7% | 0.3% | -5.9% | -4.2% | -8.5% | -1.9% | -11.3% | 5.6% | -11.7% | -12.3% | -9.8% |
| — | -3422.2% | -206.4% | +69.0% | +101.6% | +102.0% | +129.9% | -4238.5% | -58.2% | +8.5% | +9.3% | +113.5% | +47.5% | -175.6% | +27.6% | +84.6% | -15.2% | +141.6% | -7.2% | +6.3% | -16.3% | |
| ROIC | 23.2% | — | — | — | — | — | 38.2% | -39.7% | — | -261.6% | — | 85.1% | -31.2% | -13.0% | -46.2% | — | -333.0% | 129.5% | -186.7% | -86.4% | -78.4% |
| — | — | — | — | — | — | — | -146.7% | — | -1906.8% | — | — | +90.6% | -110.1% | +75.3% | — | -324.8% | +250.4% | -343.0% | -169.1% | -336.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 6.63 | 2.16 | 0.46 | 1.59 | 1.26 | 1.83 | 2.20 | — | — | — | — | — | — | — | — | 19.08 | 7.28 | 2.16 | 5.18 | 1.84 | 0.90 |
| — | +18.1% | -79.3% | — | — | — | — | — | — | — | — | — | — | — | — | +937.9% | +710.7% | +203.1% | +784.2% | +260.4% | +171.0% | |
| Debt / EBITDA | 8.73 | — | — | — | 11.03 | 3.70 | 3.92 | — | — | 152.73 | — | 4.46 | — | 280.46 | — | 32.51 | — | 3.09 | — | — | — |
| — | — | — | — | — | -97.6% | — | — | — | -45.5% | — | -86.3% | — | +8983.6% | — | — | — | — | — | — | — | |
| Current Ratio | 1.13 | 1.43 | 1.40 | 1.55 | 1.94 | 1.98 | 2.23 | 1.41 | 1.52 | 1.04 | 1.70 | 1.18 | 1.38 | 1.28 | 1.46 | 1.43 | 1.26 | 1.30 | 1.19 | 1.04 | 1.74 |
| — | -27.8% | -37.3% | +10.4% | +27.1% | +89.2% | +31.5% | +18.9% | +10.8% | -18.7% | +16.7% | -17.2% | +8.8% | -1.3% | +22.1% | +37.6% | -27.6% | -34.9% | -43.6% | -47.7% | -19.0% | |
| Quick Ratio | 1.04 | 1.35 | 1.33 | 1.46 | 1.80 | 1.84 | 2.02 | 1.21 | 1.21 | 0.82 | 1.31 | 1.03 | 1.14 | 1.06 | 1.21 | 1.26 | 1.05 | 1.15 | 1.04 | 0.90 | 1.57 |
| — | -26.7% | -34.3% | +20.8% | +48.3% | +123.3% | +53.5% | +17.6% | +5.9% | -22.3% | +8.9% | -18.8% | +8.9% | -7.7% | +16.4% | +40.6% | -32.9% | -35.2% | -44.1% | -45.8% | -6.1% | |
| Interest Coverage | 0.85 | -1.88 | -2.90 | -1.33 | 1.24 | 1.04 | 1.79 | -2.32 | -2.01 | -3.83 | -5.72 | 1.43 | -9.28 | -5.80 | -16.22 | 4.75 | -12.69 | 6.85 | -11.33 | -11.30 | -10.71 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AKBA stock.
Akebia Therapeutics, Inc.'s current P/E is -44.8x. The average P/E over the last 1 quarters is 341.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Akebia Therapeutics, Inc.'s current operating margin is 9.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Akebia Therapeutics, Inc.'s business trajectory between earnings reports.